histamine has been researched along with Cataleptic Attacks in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether histamine cells are altered in human narcolepsy with cataplexy and in animal models of this disease." | 7.79 | Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. ( Cornford, M; John, J; McGregor, R; Nishino, S; Ohtsu, H; Ramanathan, L; Sakai, N; Siegel, JM; Stone, C; Thannickal, TC; Yamanaka, A, 2013) |
| "To examine whether cerebrospinal fluid (CSF) histamine contents are altered in human narcolepsy and whether these alterations are specific to hypocretin deficiency, as defined by low CSF hypocretin-1." | 7.75 | Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. ( Mignot, E; Nevsimalova, S; Nishino, S; Sakurai, E; Watanabe, T; Yanai, K; Yoshida, Y, 2009) |
| "To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency." | 7.75 | CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. ( Chiba, S; Inoue, Y; Kanbayashi, T; Kodama, T; Kondo, H; Nishino, S; Satoh, S; Shimizu, T, 2009) |
| "In these rare patients with cataplexy without baseline hypocretin deficiency, CSF markers should be monitored over time with potential for immune therapies in early stages to try limiting hypocretin neuron loss." | 5.46 | Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( Barateau, L; Chenini, S; Dauvilliers, Y; Evangelista, E; Jaussent, I; Lopez, R; Robert, P, 2017) |
| "Sleep attacks fragmenting wakefulness, cataplexy, excess rapid-eye-movement sleep (R) during the activity period, and enhanced increase of arterial pressure during R, which are hallmarks of narcolepsy in mice, did not occur in HDC-KO, whereas they were observed in DM mice." | 5.42 | Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency. ( Bastianini, S; Berteotti, C; Cohen, G; Lin, JS; Lo Martire, V; Ohtsu, H; Silvani, A; Zoccoli, G, 2015) |
| "To determine whether histamine cells are altered in human narcolepsy with cataplexy and in animal models of this disease." | 3.79 | Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. ( Cornford, M; John, J; McGregor, R; Nishino, S; Ohtsu, H; Ramanathan, L; Sakai, N; Siegel, JM; Stone, C; Thannickal, TC; Yamanaka, A, 2013) |
| "To examine whether cerebrospinal fluid (CSF) histamine contents are altered in human narcolepsy and whether these alterations are specific to hypocretin deficiency, as defined by low CSF hypocretin-1." | 3.75 | Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. ( Mignot, E; Nevsimalova, S; Nishino, S; Sakurai, E; Watanabe, T; Yanai, K; Yoshida, Y, 2009) |
| "To (1) replicate our prior result of low cerebrospinal fluid (CSF) histamine levels in human narcolepsy in a different sample population and to (2) evaluate if histamine contents are altered in other types of hypersomnia with and without hypocretin deficiency." | 3.75 | CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. ( Chiba, S; Inoue, Y; Kanbayashi, T; Kodama, T; Kondo, H; Nishino, S; Satoh, S; Shimizu, T, 2009) |
| "Histamine was first identified in the brain about 50 years ago, but only in the last few years have researchers gained an understanding of how it regulates sleep/wake behavior." | 2.61 | Histamine: neural circuits and new medications. ( Dauvilliers, Y; Franks, NP; Jackson, AC; Scammell, TE; Wisden, W, 2019) |
| "In these rare patients with cataplexy without baseline hypocretin deficiency, CSF markers should be monitored over time with potential for immune therapies in early stages to try limiting hypocretin neuron loss." | 1.46 | Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy. ( Barateau, L; Chenini, S; Dauvilliers, Y; Evangelista, E; Jaussent, I; Lopez, R; Robert, P, 2017) |
| "Sleep attacks fragmenting wakefulness, cataplexy, excess rapid-eye-movement sleep (R) during the activity period, and enhanced increase of arterial pressure during R, which are hallmarks of narcolepsy in mice, did not occur in HDC-KO, whereas they were observed in DM mice." | 1.42 | Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency. ( Bastianini, S; Berteotti, C; Cohen, G; Lin, JS; Lo Martire, V; Ohtsu, H; Silvani, A; Zoccoli, G, 2015) |
| " As ciproxifan and thioperamide are inhibitors of cytochrome P450 enzymes, responsible for metabolizing risperidone and haloperidol, the possibility that the augmentation of antipsychotics by imidazoles resulted from drug-drug interactions was tested." | 1.33 | Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. ( Ballard, ME; Cowart, M; Decker, MW; Esbenshade, TA; Faghih, R; Fox, GB; Hancock, AA; Pan, L; Roberts, S; Rueter, LE; Zhang, M, 2005) |
| "In prior work, we reported that, during cataplexy, noradrenergic neurons cease discharge, and serotonergic neurons greatly reduce activity." | 1.32 | Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. ( Boehmer, LN; John, J; Siegel, JM; Wu, MF, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lopez, R | 1 |
| Barateau, L | 1 |
| Evangelista, E | 1 |
| Chenini, S | 1 |
| Robert, P | 1 |
| Jaussent, I | 1 |
| Dauvilliers, Y | 2 |
| Scammell, TE | 2 |
| Jackson, AC | 1 |
| Franks, NP | 1 |
| Wisden, W | 1 |
| John, J | 2 |
| Thannickal, TC | 1 |
| McGregor, R | 1 |
| Ramanathan, L | 1 |
| Ohtsu, H | 3 |
| Nishino, S | 3 |
| Sakai, N | 1 |
| Yamanaka, A | 1 |
| Stone, C | 1 |
| Cornford, M | 1 |
| Siegel, JM | 2 |
| Bastianini, S | 2 |
| Silvani, A | 2 |
| Berteotti, C | 2 |
| Lo Martire, V | 2 |
| Cohen, G | 1 |
| Lin, JS | 2 |
| Zoccoli, G | 2 |
| Mochizuki, T | 1 |
| Sakurai, E | 1 |
| Nevsimalova, S | 1 |
| Yoshida, Y | 1 |
| Watanabe, T | 1 |
| Yanai, K | 1 |
| Mignot, E | 1 |
| Kanbayashi, T | 1 |
| Kodama, T | 1 |
| Kondo, H | 1 |
| Satoh, S | 1 |
| Inoue, Y | 1 |
| Chiba, S | 1 |
| Shimizu, T | 1 |
| Sinton, CM | 1 |
| Wu, MF | 1 |
| Boehmer, LN | 1 |
| Zhang, M | 1 |
| Ballard, ME | 1 |
| Pan, L | 1 |
| Roberts, S | 1 |
| Faghih, R | 1 |
| Cowart, M | 1 |
| Esbenshade, TA | 1 |
| Fox, GB | 1 |
| Decker, MW | 1 |
| Hancock, AA | 1 |
| Rueter, LE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Signal Based Monitoring System for CNS Hypersomnias : A 10-year Longitudinal Study[NCT05443373] | 600 participants (Anticipated) | Observational | 2020-06-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for histamine and Cataleptic Attacks
| Article | Year |
|---|---|
Histamine: neural circuits and new medications.
Topics: Animals; Cataplexy; gamma-Aminobutyric Acid; Histamine; Humans; Hypothalamic Area, Lateral; Narcolep | 2019 |
Orexin/hypocretin plays a role in the response to physiological disequilibrium.
Topics: Adaptation, Physiological; Animals; Arousal; Brain; Cataplexy; Dopamine; Energy Metabolism; gamma-Am | 2011 |
9 other studies available for histamine and Cataleptic Attacks
| Article | Year |
|---|---|
Temporal Changes in the Cerebrospinal Fluid Level of Hypocretin-1 and Histamine in Narcolepsy.
Topics: Adolescent; Adult; Biomarkers; Cataplexy; Child; Female; Histamine; Histocompatibility Testing; HLA- | 2017 |
Greatly increased numbers of histamine cells in human narcolepsy with cataplexy.
Topics: Adult; Aged, 80 and over; Animals; Brain; Cataplexy; Cell Count; Disease Models, Animal; Dogs; Femal | 2013 |
Histamine Transmission Modulates the Phenotype of Murine Narcolepsy Caused by Orexin Neuron Deficiency.
Topics: Animals; Body Weight; Cardiovascular System; Cataplexy; Energy Intake; Female; Gene Knockout Techniq | 2015 |
High-amplitude theta wave bursts characterizing narcoleptic mice and patients are also produced by histamine deficiency in mice.
Topics: Animals; Blood Pressure; Cataplexy; Histamine; Histidine Decarboxylase; Humans; Male; Mice; Mice, Kn | 2016 |
Is low histamine a fundamental cause of sleepiness in narcolepsy and idiopathic hypersomnia?
Topics: Brain; Cataplexy; Disorders of Excessive Somnolence; Histamine; Humans; Intracellular Signaling Pept | 2009 |
Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.
Topics: Adult; Cataplexy; Disorders of Excessive Somnolence; Female; Histamine; Humans; Intracellular Signal | 2009 |
CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Cataplexy; Central Nervous System Stimulants; | 2009 |
Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior.
Topics: Action Potentials; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Cataplexy; Dise | 2004 |
Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Benzofurans; Brain Chemistry; Cataplexy; Cytochrome P-450 Enzyme Syst | 2005 |